Latest News

Public Health Notice

Sunday July 22 nd 2018

OTTAWA, July 21, 2018 /CNW/ - Original Notice

Why you should take note?

The Public Health Agency of Canada is collaborating with provincial public health partners, the Canadian Food Inspection Agency and Health Canada to investigate outbreaks of Salmonella Enteritidis infections in three provinces linked to frozen raw breaded chicken products.

As part of these outbreak investigations, the Canadian Food Inspection Agency issued food recall warnings on July 20, 2018 and July 21, 2018 for the following products:

  • No Name brand Chicken Nuggets (907g), with a best before date of May 15, 2019 on the outer package and a lot code of 1358M on the inner package. UPC – 0 60383 89685 0. The product was distributed nationally.
  • Unbranded $10 Chicken Fries (1.81kg), with a best before date of March 23, 2019. UPC – 0 60249 01411 4. The product was distributed nationally.

Canadians are advised not to consume the recalled products, and retailers and restaurants are advised to not serve the recalled products.

Frozen breaded chicken products containing raw poultry pose an increased health risk to individuals who handle, prepare or consume these types of foods. The Public Health Agency of Canada advises Canadians to follow proper food safety practices when handling, preparing or consuming frozen raw breaded chicken products such as chicken burgers, nuggets, strips, and chicken fries.

These outbreaks are a reminder that Salmonella can be present in various frozen raw breaded chicken products. Illnesses can be avoided by following cooking instructions carefully and verifying the internal temperature after cooking, as recommended, before consuming these products. Frozen raw breaded chicken products must be cooked to an internal temperature of at least 74°C (165°F) to ensure that they are safe to eat.

Investigation Summary

Currently, there are 7 cases of Salmonella Enteritidis illness in three jurisdictions: British Columbia (3), Alberta (1), and Ontario (3). One person has been hospitalized. No deaths have been reported. Individuals became sick in June 2018. The average age of cases is 12 years, with ages ranging from 1 to 42 years. The majority of cases (57%) are male.  

Based on the findings from the investigations to date, exposure to frozen raw breaded chicken products has been identified as the source of illness. Several of the ill individuals involved in the outbreaks reported eating No Name brand Chicken Nuggets (907g) or unbranded $10 Chicken Fries (1.81kg) before their illness occurred. Food samples of these products, No Name brand Chicken Nuggets, with a best before date of May 15, 2019 on the outer package and a lot code of 1358M on the inner package and unbranded $10 Chicken Fries, with a best before date of March 23, 2019, tested positive for Salmonella Enteritidis. The positive food samples had genetic fingerprints (using whole genome sequencing) that matched the genetic fingerprints of the cases of human illness reported in these outbreaks. As part of the food safety investigation, the Canadian Food Inspection Agency issued food recall warnings for the contaminated products. The CFIA is working with industry to ensure that these products are removed from the retail market. The investigation is ongoing, and it is possible that more products linked to the outbreak investigations will be identified. The public health notice will be updated as the investigations evolve.

Who is most at risk?

Anyone can become sick with a Salmonella infection, but infants, children, seniors and those with weakened immune systems are at higher risk of serious illness because their immune systems are more fragile.

Most people who become ill from a Salmonella infection will recover fully after a few days. It is possible for some people to be infected with the bacteria and not get sick or show any symptoms, but to still be able to spread the infection to others.

What you should do to protect your health?

Check to see whether you have the recalled frozen raw breaded chicken products in your home or place of business. If you do:

  • Do not use or eat the recalled products. Secure the recalled products in a plastic bag and then either throw them out or return them to the store where they were purchased.
  • If you do not have the original packaging of a frozen raw breaded chicken product and you are unsure of whether it is included in the food recall warnings, throw it out just to be safe.

Wash your hands with soap and warm water immediately following any contact with a recalled product.

Beyond recalled food items, frozen raw breaded chicken products may appear to be pre-cooked or browned, but they may contain raw chicken and should be handled and prepared no differently than other raw poultry products.

If you are preparing breaded chicken products, such as nuggets, strips, burgers or fries, the following precautions should be taken to protect your health:

  • Do not eat raw or undercooked frozen breaded chicken products. Cook all frozen breaded chicken products to an internal temperature of at least 74°C (165°F) to ensure that they are safe to eat. Use a digital food thermometer to verify the temperature. Insert the digital food thermometer through the side of the product, all the way to the middle. Oven-safe meat thermometers that are designed for testing whole poultry and roasts during cooking are not suitable for testing nuggets, strips or burgers.
  • Microwave cooking of frozen raw breaded poultry products, including chicken nuggets, strips, burgers or fries, is not recommended because of the possibility of uneven heating.
  • Always follow the cooking instructions on the package, including for products labelled Uncooked, Cook and Serve, Ready to Cook, and Oven Ready.
  • Wash your hands thoroughly with soap and warm water before and after handling frozen raw breaded chicken products.
  • Use a separate plate, cutting board and utensils when handling frozen raw breaded chicken products to prevent the spread of harmful bacteria.
  • Do not re-use plates, cutting boards or utensils that have come in contact with frozen raw breaded chicken products to serve the cooked product unless they have been thoroughly washed.

What are the symptoms?

Symptoms of a Salmonella infection, called salmonellosis, typically start 6 to 72 hours after exposure to Salmonella bacteria from an infected animal or contaminated product.

Symptoms include:

  • fever
  • chills
  • diarrhea
  • abdominal cramps
  • headache
  • nausea
  • vomiting

These symptoms usually last for four to seven days. In healthy people, salmonellosis often clears up without treatment. In some cases, severe illness and hospitalization may occur. People who are infected with Salmonella bacteria can be infectious from several days to several weeks. People who experience symptoms, or who have underlying medical conditions, should contact their health care provider if they suspect they have a Salmonella infection.

What is the Government of Canada doing?

The Government of Canada is committed to food safety. The Public Health Agency of Canada leads the human health investigation into an outbreak and is in regular contact with its federal, provincial and territorial partners to monitor the situation and to collaborate on steps to address an outbreak.

Health Canada provides food-related health risk assessments to determine whether the presence of a certain substance or microorganism poses a health risk to consumers.

The Canadian Food Inspection Agency conducts food safety investigations into the possible food source of an outbreak.

The Government of Canada will continue to update Canadians as new information related to these investigations becomes available.

Additional information


SOURCE Health Canada

Philanthropists Step Up With $109 Million For Alzheimer’s Research

CHICAGO, July 21, 2018 /PRNewswire/ – Philanthropists nationwide answered the call to accelerate the pace of Alzheimer’s research by giving an unprecedented $109 million to the Alzheimer’s Association for research, it was announced today at the Alzheimer’s Association International Conference® (AAIC®) 2018 in Chicago. Private philanthropy has enabled the Association to increase the pace of innovative research funding commitments to $160 million for more than 400 best-in-field projects in 21 countries.

“The only way we will achieve the national goal of effectively treating and preventing Alzheimer’s disease by 2025 is through research, and that is why we have led the charge to increase both public and private funding of Alzheimer’s research,” said Alzheimer’s Association President and CEO Harry Johns. “Research funding is the fuel for discovery and has changed the trajectory of heart disease, HIV and many cancers, and we are confident that this funding will do the same for Alzheimer’s disease. The Alzheimer’s Association is leading the way to ensure that the robust research pipeline has the money needed to make critical discoveries that will lead us to fulfill the national goal.” 

Since 2014, nearly 140 donors, including individuals, corporations and organizations, made gifts ranging from $100,000 to $5 million for research to the Alzheimer’s Association via its philanthropic initiative Step Up the Pace: Accelerating Alzheimer’s Research.

Dick Kipper of Woody Creek, Colorado, and John Beuerlein of Clayton, Missouri, served as co-chairs of the Step Up the Pace’s first phase. “I have been active in this cause for more than two decades, and the level of enthusiasm and commitment over the past four years has been unprecedented. Donors are eager to partner with the Alzheimer’s Association because of the strategic focus of the organization to accelerate research and fund new opportunities quickly in order to fuel the discovery this cause so desperately needs,” Kipper said.   

The Alzheimer’s Association is the largest nonprofit funder of Alzheimer’s disease research in the world. It is also the nonprofit with the highest impact in Alzheimer’s disease research worldwide, with its impact exceeded only by that of the U.S. and Chinese governments, according to data compiled by Thomson Reuters InCites. By increasing private philanthropy, the Association has doubled its annual funding of research projects, advancing discovery science, early detection and diagnosis, treatment and prevention.

Through Step Up the Pace, private philanthropy has enabled, expanded and enhanced 10 large-scale research projects. These include clinical trials of an innovative “drug cocktail” to treat Alzheimer’s and drug trials designed to prevent dementia symptoms before they occur.  Funded studies also include hundreds of smaller-scale investigations vetted by an international network of 6,000 dementia scientists.

The announcement comes within weeks of the U.S. Senate and House Appropriations Committees’ approval of a more than $400 million increase for Alzheimer’s and dementia research funding at the National Institutes of Health (NIH), which Alzheimer’s Association advocates have been calling for. If signed into law, this will mark the fourth consecutive year of historic increases and bring total federal funding of Alzheimer’s research to $2.3 billion annually. 

“The dramatic expansion in government funding requires an equally dramatic increase in projects to feed the pipeline,” John Beuerlein added. “The Alzheimer’s Association has an unparalleled track record for identifying and funding high-potential studies early to ensure that the pipeline is wide-ranging and scientists are enthusiastic to join this field of research.”

The results of the Association’s funding efforts have also led to the Alzheimer’s Association-led U.S. POINTER study. U.S. POINTER is a two-year clinical trial to evaluate whether lifestyle interventions that simultaneously target multiple risk factors protect cognitive function in older adults (age 60-79) at increased risk for cognitive decline. It is the first such study to be conducted in a large group of Americans.

“It’s estimated that more than one-third of global dementia cases may be preventable by addressing lifestyle factors,” said Maria Carrillo, Ph.D., chief science officer at the Alzheimer’s Association. “Heart disease and some cancers can now be effectively treated and prevented with a combination of medical and behavioral management. It’s time to see if we can see the same benefits for Alzheimer’s and other dementias.”

About the Alzheimer’s Association
The Alzheimer’s Association is the leading voluntary health organization in Alzheimer’s care, support and research. Our mission is to eliminate Alzheimer’s disease through the advancement of research, to provide and enhance care and support for all affected, and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer’s. Visit or call 800.272.3900.


Cision View original content:

SOURCE Alzheimer’s Association

Biotech IPOs For The Week Ahead

(RTTNews) – Six biotech companies launched their IPOs in the week ending July 22. Included in the listing was Tilray Inc. (TLRY), the first cannabis company to go public on a U.S. major stock exchange.

Tilray Inc. (TLRY), which made its debut on the Nasdaq Global Select Market on July 19, has so far gained as much as 87% from its listing price of $17.

Let’s take a look at the biotech companies that are going public in the week ahead.

1. Aquestive Therapeutics Inc.

Aquestive Therapeutics is a specialty pharmaceutical company with a late-stage proprietary product pipeline focused on the treatment of diseases of the Central Nervous System, or CNS.

The Company is scheduled to list its IPO on the Nasdaq Global Market, under the symbol “AQST”, on July 25.

Aquestive has offered to sell 4 million shares of its common stock in the offering, and the underwriters have an option to purchase up to 600,000 additional shares of common stock.

The initial public offering price is expected to be between $14.00 and $16.00 per share.


The Company’s most advanced proprietary product candidates include:

– Libervant (AQST-203), a buccally, or inside of the cheek, administered soluble film formulation of diazepam for the treatment of recurrent epileptic seizures, which is a phase III compound. A New Drug Application for Libervant is expected to be submitted this year.
– Sympazan (AQST-120), an oral soluble film formulation of clobazam for the treatment of seizures associated with Lennox-Gastaut Syndrome, is under FDA review, with a decision expected on August 31, 2018.
– AQST-117, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis, or ALS, which is under phase III testing.
– AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis, under phase I trials.
– AQST-305, a buccal film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors, under pre-clinical testing.

In addition to the above-mentioned product candidates, the Company also has a portfolio of the following commercialized and clinical-stage partnered products:

– Suboxone for the treatment of opioid dependence. Suboxone was launched in 2010 in partnership with Reckitt Benckiser Pharmaceuticals, Inc., which was later rebranded as Indivior plc (INVVY.OB) (INDV.L).
– Zuplenz for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, which was launched in the United States in 2015 by Midatech. Aquestive is the sole and exclusive manufacturer of Zuplenz for Midatech.
– APL-130277, proposed as an intermittent therapy to overcome episodic off periods in Parkinson’s disease. The NDA for APL-130277, submitted by the Company’s partner Sunovion Pharmaceuticals Inc., is under FDA review, with a decision expected on January 29, 2019.
– AQST-119, a vasodilator for the treatment of erectile dysfunction, is under FDA review, with a decision anticipated on November 18, 2018. The Company is seeking a commercialization partner for AQST-119.

2. Liquidia Technologies Inc.

Liquidia Technologies is a late-stage clinical biopharmaceutical company, currently focused on the development of two product candidates for the treatment of pulmonary arterial hypertension and local post-operative pain.

The Company is scheduled to list its IPO on the Nasdaq Capital Market, under the symbol “LQDA” on July 26.

Liquidia has offered to sell 4.54 million shares of its common stock in the offering, and the underwriters have an option for a period of 30 days to purchase an additional 681,818 shares of common stock.

The initial public offering price is expected to be between $10.00 and $12.00 per share.


The lead drug candidate is LIQ861 for the treatment of pulmonary arterial hypertension, or PAH.

LIQ861 is under a phase III trial, dubbed INSPIRE. This trial, initiated in January of this year, is designed to enroll at least 100 patients with PAH across multiple U.S. sites. Safety data from INSPIRE are expected in the first half of 2019.

LIQ865 for the treatment of local post-operative pain, which completed a Phase 1a clinical trial in Denmark in March 2017, and a Phase 1b clinical trial in the United States in April 2018. A Phase 2-enabling toxicology studies are expected to be initiated in the second half of 2018.

Meet the campaigners who say they will stop at nothing in their quest to break up Facebook

Monika BickertHouse Judiciary Committee/YouTube

  • Campaign group Freedom from Facebook protested at a congressional hearing this week by holding up an image of Mark Zuckerberg and Sheryl Sandberg as a two-headed octopus.
  • It was a stunt designed to raise awareness for Freedom from Facebook’s mission to break up Facebook and make it more accountable.
  • Organiser Sarah Miller said the group plans to fight Facebook for as long as it takes to bring about change, telling Business Insider that the health of democracy depends on it.
  • Freedom from Facebook has several coalition partners, including the Communications Workers of America union, while 10,000 people have signed its petition to the Federal Trade Commission.

Monika Bickert was in the witness stand ready to give evidence to Congress. As one of Facebook’s most senior executives, she was about to be grilled by the House Judiciary Committee on fake news and content filtering.

Bickert, Facebook’s head of global policy management, began delivering her opening remarks when at least four protestors held aloft signs featuring an image of Mark Zuckerberg and Sheryl Sandberg as a two-headed octopus. Moments later, the protestors walked out.

The bizarre moment piqued interest, with journalists following the congressional hearing, including BuzzFeed’s Ryan Mac, writing about the incident. As it turned out, it was the latest stunt to be organised Freedom from Facebook, a campaign group that wants to break up the social network.

Freedom from Facebook is a coalition of privacy and anti-monopoly advocacy groups, essentially born out of the Open Markets Institute in May. It counts at least nine other groups among its coalition and last week added its most powerful ally yet: The Communications Workers of America union, which represents 700,000 US workers.

Sarah Miller, the deputy director of the Open Markets Institute and spokeswoman for Freedom from Facebook, said the group was created in the heat of Cambridge Analytica scandal, which started “animating groups that we’d never seen have any sort of shared mission.”

facebook ceo mark zuckerbergChip Somodevilla/Getty Images

Freedom from Facebook has three key objectives: Separating Facebook, Instagram, WhatsApp, and Messenger; forcing Facebook to be interoperable with competing social networks; and introducing strong privacy rules to protect Facebook users.

“Mark Zuckerberg has far too much power, his own shareholders called him a dictator,” Miller said. “The set of positions that we’re offering are returning to a more responsible, reasonable status quo.”

This is not a flash in the pan issue, we are committed to finishing this job, and the health of our democracy depends on it

More than 10,000 people have signed its petition to the Federal Trade Commission, while Miller is in talks with several other organisations to join the campaign.

They intend to contribute to the FTC’s public hearings on competition and consumers over the coming months. It is the first time the FTC a conducted such a consultation in more than 20 years.

Miller would not disclose Freedom from Facebook’s financial backers, believing that anonymity is important when “we go up some of the most powerful organisations.” She stressed, however, that the coalition is in it for the long haul.

“This is not a flash in the pan issue, we are committed to finishing this job, and we feel like the health of our democracy depends on it,” Miller added.

She said the EU’s record $5 billion fine of Google this week over its abuse of Android shows a growing appetite to tackle the dominance of Silicon Valley giants. It is a question of “when not if” Facebook will face scrutiny, Miller said.

So, you can expect to see more protests like the one in Congress this week, even if it attracted attention for the wrong reasons. Some observers suggested that the octopus image, with CEO Zuckerberg and COO Sandberg, was anti-Semitic, given similar imagery was used in Nazi propaganda. Both Zuckerberg and Sandberg are Jewish.

Miller said the designer, Eddie Vale, is Jewish himself and there was “no intention” for it to be anti-Semitic. She said the design was a “riff” on the classic Standard Oil cartoon by Joseph Keppler.

Freedom from Facebook1Wikimedia Commons/Freedom from Facebook/Eddie Vale

Facebook declined to comment, but pointed Business Insider to quotes in Axios when Freedom from Facebook launched. The company argued that regulators reviewed Facebook’s acquisitions of WhatsApp and Instagram and concluded they didn’t harm competition.

And speaking on to Recode’s Kara Swisher this week, Zuckerberg made the case against Facebook being broken up. He said clipping the wings of firms like Facebook would open the door to companies from countries like China to fill the void. Companies which “do not share the values that we have,” Zuckerberg said, and would not be willing to cooperate when things go wrong for US users.

“You can bet that if the government hears word that it’s election interference or terrorism, I don’t think Chinese companies are going to wanna cooperate as much and try to aid the national interest there,” he said.

Tueller & Gibbs, LLP to Participate in Showcasing Transfer Warehouse

TELLURIDE, Colo., July 22, 2018 /PRNewswire-PRWeb/ – Tueller Gibbs, LLP, headed by Doug Tueller and Andy Gibbs, supports the transformation of this historic structure into a cultural and architectural landmark through fundraising efforts. “Community service is a core value of our firm,” Tueller said. “We devote a significant portion of our firm’s resources to pro bono and community service endeavors.”

According to the Telluride Arts website, “The Warehouse will be an extraordinary home for the arts at the heart of our community. The sandstone of the National Historic Landmark will encase stunning contemporary spaces that will host programming that advances the intellectual and cultural life of Telluride.” With assistance from Tueller Gibbs, the organization finalized the purchase of The Warehouse in April 2018, an important step for the implementation of the Telluride Cultural Master Plan adopted in 2012. As a condition of the sale and to assure the safety and stability of the building, the existing stone walls have been completely restored by master stonemasons. In a 2017 Telluride Daily Planet article about the project’s final design stage, Kate Jones, executive director of Telluride Arts was quoted saying, “The walls are protected more than they have been for 40 years since the roof caved in. . . .The building is in great shape.”

Tueller Gibbs also intends to participate in the upcoming 2018 Telluride Art + Architecture Weekend July 21 and 22, 2018. The weekend is, according to the Telluride Art and Architecture website, “The ultimate home tour for the connoisseur. Linger at each venue for an intimate peek into the work of our local architects, designers, artists, and chefs who provide home tours, art exhibits, performances, and food and wine tastings at each stop on the tour.”

Tickets may be purchased at the Telluride Arts Headquarters, 135 W. Pacific Avenue (across from the Library), July 16 through July 20 from 12 to 6 p.m. and July 21 from 10 to 4 p.m.; or at the Mountain Village Market, located at 455 Mountain Village Blvd., July 22, from 10 to 4 p.m.Advance purchase of tickets is recommended, since the event has sold out the last two years.

LTL Architects (Lewis.Tsurumaki.Lewis), a design intensive architecture firm, was selected from three finalists in the design competition. The Telluride Arts website quotes LTL’s David Lewis as saying, “Our design for Transfer Warehouse transforms the space through a creative engagement between old and new, past, present and future, between flexible and highly calibrated spaces.” The building, in its current roofless state, is open for both public and private events in the Telluride Arts District.

About Tueller Gibbs, LLP
Tueller Gibbs, LLP is structured to represent national companies and small enterprises, as well as individuals dealing with local challenges. Its transactional and litigation attorneys work together as a team providing experiential depth to creatively and pragmatically navigate complex issues. For more information, please call (303) 854-9121, or visit

For media inquiries, please call the NALA at 805.650.6121, ext. 361.


SOURCE Tueller Gibbs, LLP